Novo Nordisk To Restrict Initial Wegovy Sales In China Amid High Demand
Novo Nordisk To Restrict Initial Wegovy Sales In China Amid High Demand
Novo Nordisk A/S (NYSE:NVO) plans to limit initial sales of its obesity treatment Wegovy in China as the Danish drugmaker faces the challenge of balancing demand while ensuring global supply.
丹麦药企诺和诺德（Novo Nordisk A/S）计划在中国限制肥胖症治疗药物Wegovy的初步销售，面对全球供应保障与市场需求之间的挑战。
China's National Health Commission survey revealed over half of its 1.4 billion population is overweight or obese.
我国国家卫生健康委员会的一项调查发现，超过14亿人口中超过一半的人超重或肥胖。
Also Read: Novo Nordisk's Older Generation Weight-Loss Drug Saxenda Associated With Decreased Bone Mass Density, Study Shows.
还阅读：诺和诺德的老一代减重药Saxenda与骨密度减少有关的研究结果。
Maziar Mike Doustdar, Novo Nordisk's chief of international operations, stated the company aims to launch Wegovy in China soon, prioritizing continuous supply without affecting availability elsewhere.
诺和诺德的国际业务总监Maziar Mike Doustdar表示，该公司计划很快在中国推出Wegovy，优先考虑连续供应而不影响其他地区的可用性。
China's health authorities recently approved Wegovy, offering a new weight loss option in a market where Novo Nordisk's diabetes drug, Ozempic, has been used off-label to shed weight.
中国的卫生主管部门最近批准了Wegovy，为市场提供了一种新的减重选择，而诺和诺德的糖尿病药物Ozempic已被用于减肥的非标签使用。
As urbanization drives obesity rates, China's market for GLP-1 drugs like Wegovy could reach 40 billion yuan ($5.5 billion) by 2030, Bloomberg notes, citing HSBC analysis.
随着城市化推动肥胖率不断攀升，根据汇丰银行分析，中国对GLP-1类药物（如Wegovy）的市场规模到2030年可能会达到400亿元人民币（55亿美元）。
However, Novo Nordisk's patent on semaglutide, Wegovy's active ingredient, expires in 2026, with Hangzhou Jiuyuan Gene Engineering Co. and Livzon Pharmaceutical Group Inc. already seeking to produce generic versions.
然而，Wegovy的活性成分Semaglutide的专利将在2026年到期，杭州九元基因工程有限公司和立博药业集团已经寻求生产仿制药。
Eli Lilly And Co (NYSE:LLY) is also a key competitor, with its obesity drug under review in China. Lilly and Innovent Biologics Inc. are also developing a local weight-loss drug that is expected to launch next year.
礼来公司（Eli Lilly And Co）也是一家重要的竞争者，其肥胖症药物正在中国审批中。礼来公司和信达生物股份有限公司还在开发本地减肥药物，预计明年推出。
Bloomberg report adds that Novo Nordisk has struggled to meet global demand for Wegovy and Ozempic, but it continues to manufacture semaglutide in Denmark and North Carolina and is planning final production stages in China.
彭博社的报道称，诺和诺德一直在努力满足Wegovy和Ozempic的全球需求，但仍在丹麦和北卡罗莱纳州生产Semaglutide，并计划在中国进行最终生产阶段。
A 4 billion yuan factory expansion in Tianjin was announced in March.
3月份宣布在天津进行40亿元的工厂扩建。
While China's national health insurance covers Ozempic for diabetes, Wegovy is unlikely to receive similar reimbursement.
虽然我国的国家医保覆盖了糖尿病患者的Ozempic，但Wegovy不太可能获得类似的报销。
As a result, Wegovy will likely target those able to pay out-of-pocket, allowing Novo Nordisk to set prices independently.
因此，Wegovy可能会瞄准那些能够自己支付的人，让诺和诺德能够自主定价。
Currently, Ozempic is available on major Chinese platforms like JD.com Inc (NASDAQ:JD) and Alibaba Group Holding Ltd.'s (NYSE:BABA) Tmall.
目前，Ozempic可以在中国主要平台，如京东和阿里巴巴旗下的天猫上购买。
Price Action: NVO shares are down 0.10% at $143.52 at last check Thursday.
据最新资料，纽交所上诺和诺德的股票NVO，周四收盘价为143.52美元，下跌0.10%。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免责声明：本文部分内容使用了Benzinga Neuro的帮助。此内容是通过AI工具部分制作的，并由Benzinga编辑进行了审查和发布。
Photo by Tobias Arhelger via Shutterstock
图片由shutterstock提供